PAPriya Abraham

Priya Abraham

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Priya Abraham has a total of 117 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Time-Resolved Transcriptomic Profiling of Chandipura Virus Infection Reveals Dynamic Host Responses and Host-Directed Therapeutic Targets

    by Dhwani Jhala, Prachi Shah, Dhruvi Shah, Ishan Raval, Apurvasinh Puvar, Snehal Bagatharia, Naveen Kumar, Chaitanya Joshi, Amrutlal K. Patel

    Chandipura virus (CHPV) is a neurotropic rhabdovirus associated with recurrent outbreaks of acute encephalitis in children and a high case fatality rate, particularly in India. Despite its public health relevance, the host molecular processes governing CHPV infection and disease progression remain poorly defined. To address this gap, we conducted a time-resolved transcriptomic analysis to characterize host responses to CHPV infection and to explore host-directed therapeutic opportunities. Human HEK293T cells were infected with CHPV, followed by RNA sequencing (RNA-seq) at 6, 12, 18, and 24 h post infection (hpi). Transcriptome profiling revealed a temporally ordered host response. At 6 hpi, CHPV infection was dominated by strong activation of innate immune and inflammatory pathways, including interferon-stimulated genes and cytokine signaling. Antiviral responses persisted at 12 hpi, accompanied by suppression of metabolic and translational processes, indicating a shift in host cellular priorities. By 18 hpi, metabolic reprogramming—particularly involving lipid and sphingolipid metabolism—was observed alongside altered immune signaling, consistent with viral exploitation of host cellular machinery. At 24 hpi, repression of genes involved in chromatin organization, RNA processing, spliceosome assembly, and ribosome biogenesis reflected a global transcriptional shutdown associated with cytopathic effects. Integration of temporal transcriptomic signatures enabled identification of host pathways amenable to pharmacological targeting. Selected host-directed compounds were evaluated in vitro and exhibited antiviral activity against CHPV in a neuronal cell line. Collectively, this study provides the first time-resolved transcriptomic landscape of CHPV infection in human cells and identifies host-targeted strategies relevant for antiviral development.


  • Open Access

    ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in Syrian Hamsters against SARS-CoV-2 Infection

    by Pragya D. Yadav, Sanjeev Kumar Mendiratta, Sreelekshmy Mohandas, Arun K. Singh, Priya Abraham, Anita Shete, Sanjay Bandyopadhyay, Sanjay Kumar, Aashini Parikh, Pankaj Kalita, et al.

    We have developed a monoclonal antibody (mAb) cocktail (ZRC-3308) comprising of ZRC3308-A7 and ZRC3308-B10 in the ratio 1:1 for COVID-19 treatment. The mAbs were designed to have reduced immune effector functions and increased circulation half-life. mAbs showed good binding affinities to non-competing epitopes on RBD of SARS-CoV-2 spike protein and were found neutralizing SARS-CoV-2 variants B.1, B.1.1.7, B.1.351, B.1.617.2, and B.1.617.2 AY.1 in vitro. The mAb cocktail demonstrated effective prophylactic and therapeutic activity against SARS-CoV-2 infection in Syrian hamsters. The antibody cocktail appears to be a promising candidate for prophylactic use and for therapy in early COVID-19 cases that have not progressed to severe disease.


  • Open Access

    Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin

    by Rajni Kant, Gaurav Dwivedi, Kamran Zaman, Rima R Sahay, Gajanan Sapkal, Himanshu Kaushal, Dimpal A Nyayanit, Pragya D Yadav, Gururaj Deshpande, Rajeev Singh, et al.

    COVID-19 vaccination program was rolled out in India on January 16th 2021. 1 The whole virion inactivated BBV152 (Covaxin) and AstraZeneca’s ChAdOx1-nCov-19 (Covishield) were the two vaccines initially included under this program. 2, 3, 4, 5 Frontline workers including healthcare professionals, elderly above the age of 60 and adults with co-morbidity were prioritized for vaccination before reaching out to all the adults. During expansion of the aforementioned vaccination program, a group of participants in the northern state of Uttar Pradesh received Covishield (CS) as the first dose followed by inadvertent administration of Covaxin (CV) as the second dose. We studied the safety and immunogenicity of this heterologous prime-boost COVID-19 vaccination. A total of 98 vaccine recipients who had completed two weeks or more after the second dose of vaccine were included in this study. Three groups of participants were recruited during May to June 2021: heterologous group (n = 18, first dose CS, second dose CV administered at an interval of six weeks), among them, 11 were male (M/F:11/7) with a median age of 62 year (IQR 54.25–69.75). A comorbid condition (hypertension) was reported in one participant. Homologous CS group (n = 40, 22 were males and the rest were female (M/F:22/18) with a median age of 65.5 years (IQR 62–69) and co-morbidity was observed among 4 participants who received two CS-vaccine doses at six weeks interval. The homologous CV-group (n = 40, two vaccine doses administered at four weeks interval including 23 females (M/F:17/23) with a median age of 56 year (IQR 45.5–63) and 3 with co-morbidities ( Supplementary Table 1 ) ( Supplementary Figure S1 ).


  • Open Access

    Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152

    by Pragya D Yadav, Rima R Sahay, Gajanan Sapkal, Dimpal Nyayanit, Anita M Shete, Gururaj Deshpande, Deepak Y Patil, Nivedita Gupta, Sanjay Kumar, Priya Abraham, et al.

    The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Delta variant (B.1.617.2), a variant of concern, was associated with the second wave of pandemic in India during March–May 2021. Delta variant has outpaced the other two sub-lineages Kappa (B.1.617.1) and B.1.617.3 and was responsible for 90% of the cases reported in India. 1 It has spread across 112 countries and found to be more infectious than the Alpha, Beta and Gamma variants. Reduced neutralization has been reported with the sera of individuals vaccinated with BNT162b2, BBV152/Covaxin and chAdOx1-s against Delta variant in recent reports. 2, 3 Delta variant has also been identified as the leading cause of breakthrough infections globally among vaccinated individuals. 4


  • Correction to: Detection of SARS‑CoV‑2 variants in India from UK returnees

    by Varsha Potdar, V. Vipat, U. Saha, S. Y. Jadhav, S. Bhardwaj, M. L . Choudhary, S. Cherian, P. Abraham

  • Detection of SARS-CoV-2 variants in India from UK returnees

    by Varsha Potdar, V. Vipat, U. Saha, S. Y. Jadhav, S. Bhardwaj, M. L . Choudhary, S. Cherian, P. Abraham


  • Open Access

    An Epidemiological Analysis of SARS-CoV-2 Genomic Sequences from Different Regions of India

    by Pragya D. Yadav, Dimpal A. Nyayanit, Triparna Majumdar, Savita Patil, Harmanmeet Kaur, Nivedita Gupta, Anita M. Shete, Priyanka Pandit, Abhinendra Kumar, Neeraj Aggarwal, et al.

    The number of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) cases is increasing in India. This study looks upon the geographic distribution of the virus clades and variants circulating in different parts of India between January and August 2020. The NPS/OPS from representative positive cases from different states and union territories in India were collected every month through the VRDLs in the country and analyzed using next-generation sequencing. Epidemiological analysis of the 689 SARS-CoV-2 clinical samples revealed GH and GR to be the predominant clades circulating in different states in India. The northern part of India largely reported the ‘GH’ clade, whereas the southern part reported the ‘GR’, with a few exceptions. These sequences also revealed the presence of single independent mutations—E484Q and N440K—from Maharashtra (first observed in March 2020) and Southern Indian States (first observed in May 2020), respectively. Furthermore, this study indicates that the SARS-CoV-2 variant (VOC, VUI, variant of high consequence and double mutant) was not observed during the early phase of virus transmission (January–August). This increased number of variations observed within a short timeframe across the globe suggests virus evolution, which can be a step towards enhanced host adaptation.


  • Open Access

    Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India

    by Sarah Cherian, Varsha Potdar, Santosh Jadhav, Pragya Yadav, Nivedita Gupta, Mousmi Das, Partha Rakshit, Sujeet Singh, Priya Abraham, Samiran Panda, et al.

    As the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic expands, genomic epidemiology and whole genome sequencing are being constantly used to investigate its transmissions and evolution. In the backdrop of the global emergence of “variants of concern” (VOCs) during December 2020 and an upsurge in a state in the western part of India since January 2021, whole genome sequencing and analysis of spike protein mutations using sequence and structural approaches was undertaken to identify possible new variants and gauge the fitness of current circulating strains. Phylogenetic analysis revealed that the predominant clade in circulation was a distinct newly identified lineage B.1.617 possessing common signature mutations D111D, G142D, L452R, E484Q, D614G and P681R, in the spike protein including within the receptor binding domain (RBD). Of these, the mutations at residue positions 452, 484 and 681 have been reported in other globally circulating lineages. The structural analysis of RBD mutations L452R and E484Q along with P681R in the furin cleavage site, revealed that these may possibly result in increased ACE2 binding and rate of S1-S2 cleavage resulting in better transmissibility. The same two RBD mutations indicated decreased binding to select monoclonal antibodies (mAbs) and may affect their neutralization potential. Experimental validation against a wider panel of mAbs, sera from vaccinees and those that recovered from natural infection needs to be studied. The emergence of such local variants through the accumulation of convergent mutations during the COVID-19 second wave needs to be further investigated for their public health impact in the rest of the country and its possibility of becoming a VOC.


  • Open Access

    Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion InactivatedSARS-CoV-2 Vaccine - BBV152

    by Brunda Ganneru, Harsh Jogdand, Vijaya Kumar Dharam, Narasimha Reddy, Sai D Prasad, Srinivas Vellimudu, Krishna M Ella, Rajaram Ravikrishnan, Amit Awasthi, Jomy Jose, et al.

    We report the development and evaluation of safety and immunogenicity of a whole virion inactivated SARS-COV-2 vaccine (BBV152), adjuvanted with aluminium hydroxide gel (Algel), or a novel TLR7/8 agonist adsorbed Algel. We used a well-characterized SARS-CoV-2 strain and an established vero cell platform to produce large-scale GMP grade highly purified inactivated antigen, BBV152. Product development and manufacturing were carried out in a BSL-3 facility. Immunogenicity was determined at two antigen concentrations (3μg and 6μg), with two different adjuvants, in mice, rats, and rabbits. Our results show that BBV152 vaccine formulations generated significantly high antigen-binding and neutralizing antibody titers, at both concentrations, in all three species with excellent safety profiles. The inactivated vaccine formulation containing TLR7/8 agonist adjuvant-induced Th1 biased antibody responses with elevated IgG2a/IgG1 ratio and increased levels of SARS-CoV-2 specific IFN-γ+ CD4 T lymphocyte response. Our results support further development for Phase I/II clinical trials in humans.


  • Open Access

    Genetic characterization of SARS-CoV-2 & implications for epidemiology, diagnostics & vaccines in India

    by Priya Abraham, Sarah Cherian, Varsha Potdar

    Indian J Med Res, Official publication of Indian Council of Medical Research,India